Table 2.
Disease characteristics of the study cohort.
| Characteristic | Value (%) | CD5+ | CD5− |
|---|---|---|---|
| Bulky disease | |||
| Yes | 34 (17.5%) | 24 | 10 |
| No | 151 (77.8%) | 89 | 62 |
| Unknown | 9 (4.6%) | 9 | 0 |
| LDH | |||
| ≥ULN | 106 (54.6%) | 74 | 32 |
| <ULN | 60 (30.9%) | 34 | 26 |
| Unknown | 28 (12.9%) | 14 | 14 |
| CD5 status | |||
| Positive * | 122 (62.9%) | ||
| CD5 > Dim | 103 (53.1%) | ||
| Negative | 72 (37.1%) | ||
| B-symptoms at presentation | |||
| Yes | 105 (54.1%) | 70 | 35 |
| No | 82 (42.3%) | 46 | 36 |
| Unknown | 7 (3.6%) | 6 | 1 |
| Extra-nodal disease | |||
| Yes | 123 (63.4%) | 74 | 49 |
| >2 sites | 51 (26.3%) | 36 | 15 |
| No | 66 (34%) | 44 | 22 |
| Unknown | 5 (2.5%) | 4 | 1 |
| Bone marrow disease | |||
| Yes | 45 (23.2%) | 37 | 8 |
| No | 133 (68.6%) | 75 | 58 |
| Unknown | 16 (8.2%) | 10 | 6 |
* Defined as any malignant CD5+ cells on flow or CD5-dim IHC.